

<b>Area</b>	Therapeutics
<b>Headquarter</b>	Toronto, Canada
<b>Countries of operation</b>	Canada
<b>Founding year</b>	2019
<b>Status</b>	Phase 1 Ready


## Summary

IntelliStem is a 12 months Pre-IND biotech company that has created the next generation of cell therapy products to target catastrophic diseases such as cancer and infectious diseases. Its first product "Super Sentinel Cells™" is an off-the-shelf product to target cancer that has shown an 80% success rate compared to 20% of incumbents in-vivo which can target both blood and solid tumors. This technology offers scalable and more efficacious solutions at a fraction of the cost of the current platforms. We hope to use investor funds to advance our assets to market through clinical trials then out-licensing and co-development.

<b>Incubator programme</b>	N/A
<b>Approvals</b>	N/A
<b>Awards</b>	<ul style="list-style-type: none"> <li>• Best Venture VC Award with \$175K prize</li> <li>• Orange County People's Choice Award</li> </ul>
<b>Patents</b>	PCT/CA2020/050515 62/934,611
<b>Revenue (last yr)</b>	null
<b>Funds raised</b>	\$2million USD
<b>Currently raising:</b>	\$10million USD

## USE OF FUNDS

■ Phase I clinical trials



Interested? Get in touch

✉ [greg@clab.ventures](mailto:greg@clab.ventures)  
<https://www.intellistemtech.com/>